Food producing animal is a global challenge in terms of antimicrobial resistance spread. Extended-spectrum betalactamase (ESBL)-producing Enterobacteriaceae are relevant opportunistic pathogens that may spread in many ecological niches of the One Health approach as human, animal and environment due to intestinal selection of antimicrobial resistant commensals in food production animals. Cattle production is a relevant ecological niche for selection of commensal bacteria with antimicrobial resistance from microbiota. Enterobacteriaceae show importance in terms of circulation of resistant-bacteria and antimicrobial resistance genes via food chain creating a resistance reservoir, setting up a threat for colonization of humans and consequent health risk. ESBL-producing Enterobacteriaceae are a threat in terms of human health responsible for life threatening outbreaks and silent enteric colonization of community populations namely the elder population. Food associated colonization is a risk difficult to handle and control. In a time of globalization of food trading, population intestinal colonization is a mirror of food production and in that sense this work aims to make a picture of ESBL-producing Enterobacteriaceae in animal production for food over the world in order to make some light in this reality of selection of resistant threats in food producing animal.
Introduction
Extended-spectrum beta-lactamases (ESBL) are enzymes responsible for the hydrolysis of oxyimino-beta-lactam antibiotics, which are important therapeutic agents for the treatment of serious human and animal infections. ESBL were first described in 1983 in Enterobacteriaceae (new taxonomy Enterobacterales) and since then, with the research of the scientific community, it has been observed that ESBL-producing Enterobacteriaceae (E-ESBL) are a real threat to human health, being responsible for 1700 deaths in the USA due to therapeutic failure in severe infections in 2013 (Adeolu et al., 2016; CDC, 2013; Knothe et al., 1983) . However, E-ESBL are not only limited to hospital environment, they are also present as human intestinal commensals (Gonçalves et al., 2016; Karanika et al., 2016) . The presence of E-ESBL in several ecological niches, as commensals in humans and animals and as environmental contaminants, is reported worldwide, however, in the last decades a niche that has raised great concern, for being able to function as a reservoir and vehicle of transmission and dissemination of E-ESBL is the production animals due to their direct connection with the food chain (Madec et al., 2017) .
Cattle are one of the main sources of animal protein, becoming one of the most consumed meat around the world and milk, one of the main constituents of the human food chain (Alexandratos and Bruinsma, 2012) . It is also one of the main sources of biological fertilizers, due to the high production of faecal mass of these animals (Smith and Williams, 2016) . All this, highlights the importance of cattle production in the context of the food chain and the contaminated environment as reservoir and transmitting/disseminating vehicle of E-ESBL, thus configuring a threat to the world public health. This circulation of E-ESBL within our ecosystem creates a consensual concern of the scientific community and of the authority involved in the One health approach (Robinson et al., 2016) .
The ESBL are enzymes that are classified in several types, being CTX-M, SHV and TEM the most prevalent around the world (Paterson and Bonomo, 2005) . However, there are other ESBL such as OXA, PER, VEB, BES, GES, SFO, TLA, and IBC (Paterson and Bonomo, 2005) . The CTX-M Table 1 . Relation of ESBL described in cattle by type of ESBL, described species, country of report, origin of the isolate and bibliographic reference of the description.
Beta-lactamase
Enterobacteriaceae Country Source Reference
CTX-M-1 Escherichia coli Europe
Germany Faecal (Wieler et al., 2011) Mastitis (Freitag et al., 2017; Michael et al., 2017) Diarrheic (Ewers et al., 2014) Sick Infection (Brennan et al., 2016) Denmark Commensal (Kjeldsen et al., 2015) ND (Garcia-Fernandez et al., 2011; Jakobsen et al., 2015) Spain Mastitis (Briñas et al., 2005) Finland Faecal (P€ aiv€ arinta et al., 2016) France Faecal Hartmann et al., 2012; Madec et al., 2008; Meunier et al., 2006) Mastitis (Dahmen et al., 2013) Diarrheic (Hartmann et al., 2012) Sick (Madec et al., 2008; Valat et al., 2016) Infection (Meunier et al., 2006) Hungary Infection (Toth et al., 2013) Portugal Faecal (Ramos et al., 2013) Mayotte ND Netherlands Faecal (Ceccarelli et al., 2019; Heuvelink et al., 2019; Hordijk et al., 2013a, b, c) United Kingdom
Faecal (Velasova et al., 2019) Infection (Hunter et al., 2010) ND (Stokes, 2014) Czech Republic Faecal (Dolejska et al., 2011b) Sick (Dolejska et al., 2013) R eunion ND Slovakia Faecal (Kme t and Buj n akov a, 2018) Sweden Faecal (Duse et al., 2015) Switzerland Faecal (Endimiani et al., 2012; Geser et al., 2012a; Zurfluh et al., 2015) Turkey Faecal (AslantaŞ et al., 2017; Pehlivanoglu et al., 2016) North America Canada ND (Cormier et al., 2019) USA Faecal (Mir et al., 2016; Mollenkopf et al., 2012; Wittum et al., 2010) Asia China Mastitis (Ali et al., 2016 (Ali et al., , 2017 South Korea Mastitis Indonesia Faecal Japan Mastitis (Ohnishi et al., 2013b) Klebsiella pneumoniaeEurope
Italy
Mastitis (Locatelli et al., 2010) Klebsiella ozaenae Italy Faecal (Stefani et al., 2014) Salmonella enterica Germany ND (Rodríguez et al., 2009 )
Germany
Faecal (Dahms et al., 2015) CTX-M-2 E. coli South America
Brazil
Faecal (Palmeira et al., 2018) Europe Germany Mastitis (Eisenberger et al., 2017; Freitag et al., 2017; Michael et al., 2017) Sick Netherlands Faecal (Ceccarelli et al., 2019; Heuvelink et al., 2019) North America
Canada
Faecal (Cormier et al., 2016) Asia Japan Faecal Diarrheic Infection (Asai et al., 2011) K. pneumoniae Japan Mastitis (Ohnishi et al., 2013a, b; Saishu et al., 2014) Klebsiella oxytoca Japan Mastitis (Ohnishi et al., 2013b) Citrobacter freundii Japan Mastitis (continued on next page) Citrobacter koseri Japan Mastitis (Ohnishi et al., 2013b) Enterobacter cloacae Japan Mastitis Enterobacter aerogenes Japan Mastitis (Ohnishi et al., 2013b) CTX-M-2/97 E. coli Europe
Netherlands
Faecal (Hordijk et al., 2013a, b, c) CTX-M-3 E. coli Europe Germany Mastitis France Faecal Netherlands Faecal (Ceccarelli et al., 2019; Hordijk et al., 2013b) United Kingdom
Infection (Hunter et al., 2010) Turkey Faecal (AslantaŞ et al., 2017; Pehlivanoglu et al., 2016) Asia China Faecal (Zheng et al., 2019) Mastitis (Ali et al., 2016 (Ali et al., , 2017 South Korea Mastitis Hong Kong Faecal CTX-M-8 E. coli Europe
Faecal (Ceccarelli et al., 2019) CTX-M-9 E. coli Europe
Faecal (Ceccarelli et al., 2019) North America USA Faecal (Poole et al., 2017) Asia Indonesia Faecal Africa Egypt Faecal Oceania Australia Sick (Abraham et al., 2015) S. enteric Australia ND (Sparham et al., 2017) CTX-M-14 E. coli Europe Germany Mastitis (Eisenberger et al., 2017; Freitag et al., 2017; Michael et al., 2017) Sick Belgium Faecal (Pardon et al., 2017) Infection (Pardon et al., 2017) France Faecal Madec et al., 2008) Mastitis (Dahmen et al., 2013) Sick (Madec et al., 2008) Wales Sick (Tyrrell et al., 2016) Netherlands Faecal (Ceccarelli et al., 2019; Heuvelink et al., 2019; Hordijk et al., 2013a, b, c) United Kingdom
Faecal (Cottell et al., 2011; Horton et al., 2011; Randall et al., 2014; Snow et al., 2011) Infection (Hunter et al., 2010) ND (Stokes, 2014; Stokes et al., 2013) Switzerland Faecal (Geser et al., 2012a; Zurfluh et al., 2015) Mastitis (Geser et al., 2012a) Asia China Faecal (Zheng et al., 2012 (Zheng et al., , 2019 Mastitis (Ali et al., 2016 (Ali et al., , 2017 South Korea Faecal (Rayamajhi et al., 2011; Tamang et al., 2013a) Sick (Lim et al., 2009) Hong Kong Faecal Japan Mastitis (Ohnishi et al., 2013b) Diarrheic Taiwan Mastitis (Su et al., 2016) North America Canada ND (Cormier et al., 2019) USA Faecal (Mollenkopf et al., 2012) Oceania (continued on next page) J. Dantas Palmeira, H.M.N. Ferreira Heliyon 6 (2020) e03206 (Abraham et al., 2015) K. pneumoniae Europe France Mastitis (Dahmen et al., 2013) Asia Japan Mastitis (Ohnishi et al., 2013b) CTX-M-15 E. coli South America
Brazil
Faecal (Sartori et al., 2017) Europe Germany Faecal (Fischer et al., 2014; Wieler et al., 2011) Mastitis (Eisenberger et al., 2017; Freitag et al., 2017; Michael et al., 2017) Sick France Faecal Sick (Madec et al., 2008) Infection Meunier et al., 2006) Madagascar ND Mayotte ND Netherlands Faecal (Ceccarelli et al., 2019; Heuvelink et al., 2019; Hordijk et al., 2013a, b, c) United Kingdom
Faecal (Horton et al., 2011; Randall et al., 2014; Watson et al., 2012) Mastitis (Timofte et al., 2014) Infection ( 
North America
Canada ND (Cormier et al., 2019) Faecal (Cormier et al., 2016) USA Faecal (Mir et al., 2016; Mollenkopf et al., 2012) Africa Egypt Faecal France Faecal Madec et al., 2008) Netherlands Faecal (Ceccarelli et al., 2019; Hordijk et al., 2013c) Turkey Faecal (Kucukbasmaci et al., 2008; Pehlivanoglu et al., 2016) Asia China Mastitis (Ali et al., 2016 (Ali et al., , 2017 K. pneumoniae Europe France Faecal United Kingdom
Mastitis (Timofte et al., 2014) Africa Egypt Mastitis (Ahmed and Shimamoto, 2011) (continued on next page) Source: ND -Not described isolate source. The virulent and multi-resistant CTX-M-15-producing E. coli O25b-ST131 clone is certainly one of the most well adapted circulant clones among E-ESBL, which is responsible for outbreaks and deaths around the world and is not related only to infectious processes, but is also reported in human intestinal colonization (elderly, adults and children) and animals (terrestrial and aquatic) and environmental contamination (Badran et al., 2016; Brahmi et al., 2015; Dolejska et al., 2011a; Ewers et al., 2010; Gonçalves et al., 2016; Namaei et al., 2017; Naseer et al., 2007; Olesen et al., 2013; Oteo et al., 2009; Owens et al., 2011; Zhong et al., 2015) .
Europe
Europe is the continent with more number of countries (n ¼ 16) with description of E-ESBL in cattle, Figure 2 shows all countries. Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Portugal, Slovakia, Spain, Sweden, Switzerland, Turkey and United Kingdom, presented at least one report of E-ESBL in cattle (AslantaŞ et al., 2017; Briñas et al., 2005; Dolejska et al., 2011b; Duse et al., 2015; Hordijk et al., 2013c; Hunter et al., 2010; Kjeldsen et al., 2015; Kme t and Buj n akov a, 2018; Michael et al., 2017; P€ aiv€ arinta et al., 2016; Pardon et al., 2017; Ramos et al., 2013; Stefani et al., 2014; Toth et al., 2013; Valat et al., 2016; Zurfluh et al., 2015) . CTX-M-1 was described in 14 of the 16 countries with E-ESBL in cattle, CTX-M-15 present in 7, CTX-M-14 in 6 and CTX-M-3 and SHV-12 in 5 (AslantaŞ et al., 2017; Briñas et al., 2005; Dolejska et al., 2011b; Duse et al., 2015; Gay et al., 2018; Haenni et al., 2014; Hordijk et al., 2013b; Hordijk et al., 2013c; Hunter et al., 2010; Kjeldsen et al., 2015; Kme t and Buj n akov a, 2018; Michael et al., 2017; P€ aiv€ arinta et al., 2016; Pardon et al., 2017; Pehlivanoglu et al., 2016; Ramos et al., 2013; Timofte et al., 2014; Toth et al., 2013; Valat et al., 2016; Zurfluh et al., 2015) . (Dahms et al., 2015; Friese et al., 2013; Michael et al., 2017; Wieler et al., 2011; Wu et al., 2013) . CTX-M-1, CTX-M-3, CTX-M-14, CTX-M-15 and SHV-12 have already been reported in E-ESBL in humans in Germany associated with infections (Gerhold et al., 2016; Mshana et al., 2009; Schmitt et al., 2007) .
The Netherlands, German neighbours, also presented high diversity and number of reports of E-ESBL in cattle. There were identified CTX- (Geser et al., 2011 (Geser et al., , 2012a Reist et al., 2013; Zurfluh et al., 2015) . They were reported in 3 species: E. coli, C. youngae and E. cloacae. All reports were of faecal origin, with the exception of 1 case of mastitis (CTX-M-14) (Geser et al., 2012a) . E-ESBL of human origin have been reported to harbour CTX-M-1, CTX-M-14 and CTX-M-15 in Switzerland (Geser et al., 2012b) .
CTX-M-1, CTX-M-15 and TEM-24 were described in E-ESBL in cattle in Italy. Reported in K. pneumoniae (mastitis) and K. ozaenae (faecal carriage). The three types of ESBL described in cattle, CTX-M-1, CTX-M-15 and TEM-24, have also been described in human clinical isolates (Mugnaioli et al., 2006; Perilli et al., 2011) .
Turkey is the second largest cattle producer in Europe and presented E-ESBL in cattle with CTX-M-1, CTX-M-3, CTX-M-15, SHV-5, SHV-12 and OXA-10 in E. coli, C. freundii and C. brakii of faecal origin (AslantaŞ et al., 2017; Kucukbasmaci et al., 2008; Pehlivanoglu et al., 2016) . CTX-M-1, CTX-M-3, CTX-M-15, SHV-5 and SHV-12 were reported in human clinical isolates in Turkish hospitals (Gur et al., 2008; Tasli and Bahar, 2005) .
The Nordic countries have few reports and diversity of betalactamases, with E-ESBL in cattle harbouring CTX-M-1 in Denmark and Finland and CTX-M-1 and CTX-M-15 in Sweden all in E. coli and of intestinal origin (Duse et al., 2015; Kjeldsen et al., 2015; P€ aiv€ arinta et al., 2016) . When analysed the description in E-ESBL of human origin, CTX-M-1 has been described in Denmark, Finland and Sweden and CTX-M-15 in Sweden (Brolund et al., 2014; Forssten et al., 2010; Jakobsen et al., 2015) .
In the Iberian Peninsula, Spain and Portugal also presented E-ESBL in cattle, with descriptions on Spain of CTX-M-1, CTX-M-55 and ND-ESBL and in Portugal of CTX-M-1 and CTX-M-32 (Briñas et al., 2005; Hern andez et al., 2017; Ramos et al., 2013) . The descriptions in both countries were in E. coli, but in Spain they were of faecal and clinical origin and in Portugal only faecal. CTX-M-1 has already been described in E-ESBL in human in Spain and CTX-M-1 and CTX-M-32 in Portugal (Fernandes et al., 2014; Novais et al., 2007) .
CTX-M-1 was described in Hungary, Czech Republic and Slovakia and CTX-M-14 in Belgium in E-ESBL in cattle. All in E. coli and with faecal and clinical origins (Dolejska et al., 2013; Kme t and Buj n akov a, 2018; Pardon et al., 2017; Toth et al., 2013) . In E-ESBL of human origin, CTX-M-1 has already been reported in Hungary, Czech Republic and CTX-M-14 in Belgium (Dolejska et al., 2013; Ebrahimi, 2016; Rodriguez-Villalobos et al., 2011) .
North America
In North America only 2 countries registered E-ESBL description in cattle, Canada and the United States, the last one being the world's largest cattle producer . CTX-M-15, CTX-M-32 and CTX-M-65 were the only beta-lactamases described in both countries, the Figure 3 shows the complete described ESBL from cattle in the North America (Cormier et al., 2016; Mir et al., 2016; Poole et al., 2017; Tate et al., 2017) .
In (Afema et al., 2018; Davis et al., 2015; Frye and Fedorka-Cray, 2007; Mir et al., 2016; Mollenkopf et al., 2012; Poole et al., 2017; Tate et al., 2017; Wittum et al., 2010) . CTX-M-1, CTX-M-14, CTX-M-15 and CTX-M-65 were reported in E-ESBL isolates from humans (Chen et al., 2014; Li et al., 2015; Tate et al., 2017; Wang et al., 2013) .
CTX ND-ESBL were described in E-ESBL in cattle in Canada, which was the country where the largest variety of CTX-M's types were described (Awosile et al., 2018; Cormier et al., 2016; Lussier, 2010) . All E-ESBLs were E. coli of faecal origin. In E-ESBL of human origin in Canada were detected similarly to cattle the CTX-M-2, CTX-M-15, CTX-M-24, CTX-M-27, CTX-M-55, CTX-M-65 and SHV-2 (Denisuik et al., 2013 (Denisuik et al., , 2015 Peirano et al., 2010; Pitout et al., 2008) .
South America
In South America E-ESBL is still poorly described, being few and incomplete, from the molecular point of view, the reports of E-ESBL in cattle in the countries of this continent. Only Brazil, Chile and Peru present reports of E-ESBL in cattle. Figure 4 shows what E-ESBL has already been described in these countries. Brazil is the world's second largest cattle producer and the world's second largest exporter of cattle . The presence of E-ESBL in cattle with CTX-M-2, CTX-M-15, CTX-M, SHV and ND-ESBL has already been described in the country (N obrega et al., 2013; Palmeira et al., 2018; Santos, 2006; Sartori et al., 2017) . Originated from mastitis or with faecal origin in E. coli and K. pneumoniae. There are several reports in human clinical E-ESBL of CTX-M-2, CTX-M-15, CTX-M and SHV in Brazil (Sampaio and Gales, 2016) .
Chile and Peru describe the presence of E-ESBL, but not described the enzymes responsible for ESBL phenotype. These reports were in E. coli in mastitis in Chile and in E. coli and E. cloacae of faecal origin in Peru (Gonzalez, 2006; Mendoza, 2017) . Both countries have reports of E-ESBL in humans (Colquechagua Aliaga et al., 2015; Hernandez et al., 2013) .
Asia
The second continent with the highest number of countries reporting E-ESBL in cattle is Asia, which shows description of E-ESBL in 13 countries (China, Hong Kong, India, Indonesia, Iran, Israel, Japan, Lebanon, Malaysia, Saudi Arabia, South Korea, Thailand and Taiwan), highlighting China and India which are the fourth and fifth largest cattle producers in the world Ali et al., 2017; Barzan et al., 2017; Diab et al., 2016; Hassan et al., 2015; Hinthong et al., 2017; Kamaruzzaman, 2015; Koovapra et al., 2016; Ohnishi et al., 2013a; Su et al., 2016; Sudarwanto et al., 2016; Tark et al., 2017) . They have different roles in the import and export scenario, as India is the world's largest exporter of cattle and China the largest importer, since its internal production is not sufficient for internal consumption . Figure 5 shows the countries and the diversity of beta-lactamases found in each of them.
China (Ali et al., 2017; Yang et al., 2018; Zheng et al., 2019) . CTX-M-3, CTX-M-14, CTX-M-15, CTX-M-55 and SHV-12 were described isolated from E-ESBL of human origin in China (Hu et al., 2013; Tian et al., 2012) .
In India CTX-M-15, CTX-M-63, CTX-M, SHV-180, SHV and TEM in E-ESBL from cattle have already been described. Faecal origin and mastitis, being detected in E. coli and K. pneumoniae (Borah et al., 2014; Das et al., 2017; Koovapra et al., 2016) . The presence of CTX-M-15 and SHV in E-ESBL in India has been reported in humans (Hawkey, 2008) .
Japan and South Korea, the 3rd and 4th largest world importers of cattle, presented E-ESBL in cattle, respectively, with CTX-M-1, CTX-M-2, CTX-M-14, CTX-M-15 and SHV-11 and CTX-M-1, CTX-M-3, CTX-M-14, CTX-M-15, CTX-M-32, and CTX-M. These were detected in faecal E-ESBL and clinical in the animals and in Japan in E. coli, K. pneumonia, K. oxytoca, C. freundii, C. koseri, E. cloacae and E. aerogenes and in South 
Oceania
In Oceania as one might imagine, due to its size and number of countries, there exist few reports of E-ESBL in cattle production. The only country with reports is Australia, which is the 6th largest world producer country and the 3rd biggest exporter . Figure 7 shows the countries with E-ESBL description in cattle and what ESBL type has been described in them.
Australia presented a description of CTX-M-9 and CTX-M-14 in E-ESBL in cattle. The description was carried out in clinical isolated and in E. coli and in S. enterica (Abraham et al., 2015; Sparham et al., 2017) . Both variants, CTX-M-9 and CTX-M-14, have already been described in human clinical isolates in Australia (Zong et al., 2008) .
Conclusion
E-ESBL are a threat to human health and are now scattered around the world in intestinal colonization and clinical processes of cattle in Europe, the Americas, Asia, Africa and Oceania. These are described in 6 of the 7 major world cattle producers and certainly these E-ESBLs are contributing to the circulation of these and the ESBL genes through the ecosystems. A circulation that does not only concern the internal level of each country, since the circulation trade of cattle and their derivatives between countries is increasing, with E-ESBL being found in the animals of the world 5 largest meat exporters.
Further studies in the various areas of each country, as well as in other countries without data, are necessary for a better understanding of the presence and circulation of these E-ESBL through cattle and the food chain to assist in the implementation of measures to help in the surveillance and control of the E-ESBL dissemination and propagation.
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